NEWS & EVENTS:

> Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

> Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in  Type 2 Diabetes at the European Association for the Study of Diabetes Conference

> Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes